Pancreatic lipase (PL) is essential for the hydrolysis of dietary triglycerides, and lipase inhibitors can produce a hypolipidemic effect, aiding in the management of metabolic disorders (Zeng et al., 2018). Here, PNLIP is linked to metabolic disease.